Abstract: Objective To evaluate the efficacy and adverse effects of lobaplatin plus capecitabine in the treatment for advanced breast cancer. Methods Twentytwo patients with advanced breast cancer accepted lobaplatin plus capecitabine chemotherapy. Lobaplatin 30mg／m2 iv 3h，d1；capecitabine 2500mg／m2 for twice daily 30min after meal with oral administration， d1d14.Three weeks was a cycle. Objective response was evaluated by RECIST 1.0 standard and adverse effects were evaluated by WHO standard.Results In the 22 patients，no one got CR，with 9 of PR，8 of SD and 5 of PD. The objective response rate was 40.9％ and the disease control rate was 77.3%. The median progressionfree survival was 8.9 months and the median overall survival was 14.2 months. The main adverse effects were gastrointestinal reaction，bone marrow suppresion and handfoot syndrome，mainly in grade 1-2. Conclusion Lobaplatin plus capecitabine regimen is effective and well tolerated for advanced breast cancer，worthy of further clinical study.